Draig Therapeutics Presents New Phase 1 Data Demonstrating Safety, Tolerability, Pulsatile PK and Target Engagement by DT-101, a Novel AMPA Receptor Potentiator, at ASCP Annual Meeting

NEWTON, Mass.--(BUSINESS WIRE)--Draig Therapeutics, a clinical-stage biopharmaceutical company developing transformative, best-in-class neuropsychiatric therapies, presented today an oral presentation and two posters at the American Society for Clinical Psychopharmacology (ASCP) Annual Meeting. Draig’s pipeline of highly specific AMPA and GABAA receptor modulators are designed to enable safe, precise modulation of the major neurocircuits underlying neuropsychiatric disorders. The Company’s lead